Noticias y Actividades de Kiromic BioPharma
Ejecutivos
Ver el organigrama con sus 7 ejecutivos principales
Biografías más buscadas en Kiromic BioPharma
- Pietro Bersani, Chief Executive Officer and Director
- Pamela Misajon, Director
- Michael Catlin, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Kiromic BioPharma.
Biotecnología
Kiromic BioPharma tiene 2.350 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnología
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 4 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Kiromic BioPharma
- Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer | Kiromic BioPharma, Inc.
- Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline | Kiromic BioPharma, Inc.
- Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate | Kiromic BioPharma, Inc.
- Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement | Kiromic BioPharma, Inc.
- Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights | Kiromic BioPharma, Inc.
- Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022 | Kiromic BioPharma, Inc.
- Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights - Kiromic BioPharma, Inc.
- Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid Tumors - Kiromic BioPharma, Inc.
- Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors - Kiromic BioPharma, Inc.
- Kiromic BioPharma, Inc. Announces Closing of Public Offering - Kiromic BioPharma, Inc.
- View more press releases Close
Redes sociales sobre Kiromic BioPharma
- Kiromic BioPharma en Wikipedia, Google News y Yahoo Finance
- Kiromic BioPharma en LinkedIn, Twitter y YouTube
